Overview
Psychedelic wellness company operating legal psilocybin mushroom retreats in Jamaica and developing metered-dose functional mushroom products. They focus on making psychedelic experiences accessible under legal jurisdictions.
Silo Wellness is a psychedelic wellness company headquartered in Portland, Oregon, that operates legal psilocybin mushroom retreats in Jamaica while simultaneously developing innovative metered-dose functional mushroom products. The company leverages Jamaica's permissive legal environment to offer supervised psychedelic experiences to clients seeking therapeutic and transformational benefits. Their proprietary metered-dose delivery format represents a meaningful technological advancement in the psychedelics space, allowing for more precise and controlled administration of psilocybin compounds. This dual-track approach positions Silo Wellness at the intersection of experiential wellness services and consumer psychedelic product development.
Silo Wellness is publicly listed on the Canadian Securities Exchange, giving it access to capital markets as the broader psychedelic industry continues to mature and attract institutional attention. The company has established an operational retreat infrastructure in Jamaica, one of the few jurisdictions globally where psilocybin experiences can be offered legally and openly to international clientele. Their work on metered-dose mushroom formulations places them ahead of many peers who remain in purely preclinical or research-oriented phases. These milestones reflect a pragmatic commercialization strategy that prioritizes near-term revenue generation alongside longer-term product development opportunities.
Silo Wellness represents an important bridge between the emerging psychedelic medicine movement and the broader neurotechnology industry, demonstrating that responsible, scalable psychedelic wellness experiences can be delivered within existing legal frameworks. Their metered-dose technology speaks directly to one of the field's central challenges, namely the lack of standardized and reproducible dosing mechanisms for psilocybin and related compounds. As regulators in the United States and elsewhere move closer to potential psychedelic-assisted therapy approvals, companies like Silo Wellness that have built operational expertise and delivery infrastructure will be well positioned to influence industry standards. Their work ultimately advances the neurotech sector's understanding of how psychedelic compounds can be responsibly integrated into mainstream mental health and wellness paradigms.
More in Psychedelics
Latest industry news
Synchron Closes $275M Series D to Accelerate Stentrode BCI Commercialization
2026-06-15 ยท Funding
MIT Researchers Demonstrate Real-Time Emotion Decoding via Non-Invasive EEG with 94% Accuracy
2026-06-13 ยท Research
Synchron Launches Stentrode Home Edition, Expanding BCI Access Beyond Clinical Settings
2026-06-11 ยท Product
Synchron Reaches 100-Patient Milestone as Stentrode BCI Moves Toward Pivotal Trial
2026-06-09 ยท Industry
Company details
Category
๐ Psychedelics
Location
Portland, OR, USA
Funding
Public ยท CSE
Website
silowellness.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages โ